Monoclonal antibody treatments for multiple sclerosis

被引：9
|
作者：
Rose, John W. [1 ]
Foley, John F. [1 ]
Carlson, Noel G. [1 ]
机构：
[1] VA Salt Lake City Hlth Care Syst, Neurovirol Res Lab, Salt Lake City, UT 84148 USA
来源：
CURRENT TREATMENT OPTIONS IN NEUROLOGY | 2009年 / 11卷 / 03期
关键词：
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; PLACEBO-CONTROLLED TRIAL; CEREBROSPINAL-FLUID; B-CELLS; SUBCUTANEOUS DACLIZUMAB; NEUROMYELITIS-OPTICA; PERIPHERAL-BLOOD; NATALIZUMAB;
D O I：
10.1007/s11940-009-0025-5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Monoclonal antibodies (MAbs) may have great potential as therapies for autoimmune diseases. Their development as treatments for multiple sclerosis (MS) is promising. Partially effective immunomodulatory therapies have been helpful for many MS patients; however, for patients failing these immunomodulatory treatments, MAbs are an important new treatment option. Currently, MAbs are approved by the US Food and Drug Administration for treatment of many conditions, including autoimmune diseases. This article reviews four MAbs that have been investigated as potential treatments for MS. Of these MAbs, natalizumab is approved for treatment of MS. The other three MAbs (alemtuzumab, rituximab, and daclizumab) are all promising therapies in development for treatment of MS. Adverse effects are relatively mild for these MAbs; however, care in administration and management of these agents is emphasized. Overall, these MAb therapies have great promise in the treatment of MS.
引用
收藏
页码：211 / 220
页数：10
相关论文
共 50 条
  • [41] Adverse events and monitoring requirements associated with monoclonal antibody therapy in patients with multiple sclerosis
    Yara Dadalti Fragoso
    Drugs & Therapy Perspectives, 2019, 35 : 627 - 634
  • [42] The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis
    Diebold, Martin
    Derfuss, Tobias
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2019, 12
  • [43] Tysabri - Natalizumab - Biogen Idec/Elan - Monoclonal antibody first to be approved for multiple sclerosis
    不详
    FORMULARY, 2004, 39 (12) : 570 - 571
  • [44] Development of anti-SEMA4D monoclonal antibody for the treatment of multiple sclerosis
    Fisher, T.
    Reilly, C.
    Winter, L.
    Veeraraghavan, J.
    Jonason, A.
    Seils, J.
    Huang, H.
    Bussler, H.
    Klimatcheva, E.
    Decker, J.
    Torno, S.
    Kirk, R.
    Cornelius, C.
    Richards, T.
    Caplan, J.
    Howell, A.
    Kenney, P.
    Scrivens, M.
    Croy, L.
    Pandina, T.
    Doherty, M.
    Seigel, G.
    Evans, E.
    Paris, M.
    Leonard, J.
    Watkins, R.
    Foster, P.
    Zauderer, M.
    Smith, E.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S206 - S206
  • [45] Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
    Coles, AJ
    Paolillo, A
    Molyneux, P
    Wing, MG
    Hale, G
    Miller, D
    Waldmann, H
    Compston, DAS
    ANNALS OF NEUROLOGY, 1998, 44 (03) : 464 - 464
  • [46] Development of anti-SEMA4D monoclonal antibody for the treatment of multiple sclerosis
    Fisher, T.
    Reilly, C.
    Winter, L.
    Veeraraghavan, J.
    Jonason, A.
    Seils, J.
    Huang, H.
    Bussler, H.
    Klimatcheva, E.
    Decker, J.
    Torno, S.
    Kirk, R.
    Cornelius, C.
    Richards, T.
    Caplan, J.
    Howell, A.
    Kenney, P.
    Scrivens, M.
    Croy, L.
    Pandina, T.
    Doherty, M.
    Seigel, G.
    Wang, W.
    Evans, E.
    Bowers, W.
    Paris, M.
    Leonard, J.
    Watkins, R.
    Foster, P.
    Zauderer, M.
    Smith, E.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 444 - 444
  • [47] Monoclonal antibody ocrelizumab for primary-progressive multiple sclerosis in adults: a systematic review
    Klabukova, D.
    Davydovskaya, M.
    Ermolaeva, T.
    Holownia-Voloskova, M.
    Polyakova, K.
    Fisun, A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S32 - S32
  • [48] Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
    Coles, AJ
    Wing, MG
    Molyneux, P
    Paolillo, A
    Davie, CM
    Hale, G
    Miller, D
    Waldmann, H
    Compston, A
    ANNALS OF NEUROLOGY, 1999, 46 (03) : 296 - 304
  • [49] Adverse events and monitoring requirements associated with monoclonal antibody therapy in patients with multiple sclerosis
    Fragoso, Yara Dadalti
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (12) : 627 - 634
  • [50] Development of anti-SEMA4D monoclonal antibody for the treatment of multiple sclerosis
    Jonason, A.
    Klimatcheva, E.
    Fisher, T.
    Reilly, C.
    Winter, L.
    Veeraraghavan, J.
    Seils, J.
    Huang, H.
    Bussler, H.
    Decker, J.
    Torno, S.
    Kirk, R.
    Cornelius, C.
    Richards, T.
    Caplan, J.
    Howell, A.
    Kenney, P.
    Scrivens, M.
    Balch, L.
    Pandina, T.
    Doherty, M.
    Seigel, G.
    Wang, W.
    Evans, E.
    Bowers, W.
    Paris, M.
    Leonard, J.
    Watkins, R.
    Foster, P.
    Zauderer, M.
    Smith, E.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 240 - 241
12345